Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Ninerafaxstat Well-Tolerated and Safe for Nonobstructive Hypertrophic Cardiomyopathy
April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with evidence of improvements in symptoms and exercise capacity among people with ...
Study Shows Web App Effective in Determining Access to Statins Without a Prescription
April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely matched the results of clinician assessments in determining a person’s eligibility ...
Plozasiran Reduces Triglyceride Levels by 74% at 24 Weeks
April 7, 2024 — In patients with severely elevated triglyceride levels at risk for developing acute pancreatitis, the investigational drug plozasiran reduced triglyceride levels by an average of 74% ...
EMPACT-MI Trial Outcomes Reported at ACC.24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack
April 6, 2024 — Use of the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin following a heart attack did not show a significant benefit in reducing overall heart failure ...

Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD)

News | Pharmaceuticals

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical company developing therapies that ...

July 10, 2024

Despite greater weight loss in women, the improvement in HF symptoms was similar between sexes, suggesting semaglutide's heart failure benefits may be, in part, independent of weight loss

News | Cardiovascular Clinical Studies

Semaglutide Leads to Greater Weight Loss in Women than Men with HF, Improves HF Symptoms in Both Sexes

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

June 26, 2024

New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness

News | Cardiovascular Clinical Studies

Analysis of INPEFA (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

June 21, 2024

Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1

News | Pharmaceuticals

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That Inpefa (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

June 5, 2024 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data ...

June 05, 2024

News | Pharmaceuticals

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That Inpefa (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

May 24, 2024 — Lexicon Pharmaceuticals, Inc. announced a new post-hoc analysis of clinical data showing that INPEFA ...

May 24, 2024

Voiant (USA) and Thirona (The Netherlands) are pleased to announce they have entered a global commercial partnership, combining Voiant's expertise in supporting clinical trials in pulmonary drug and treatment development with Thirona's expertise in advanced lung image analysis

News | Cardiovascular Business

Voiant and Thirona Announce Commercial Partnership for Full Scope Services in Imaging-based Clinical Trials for Pulmonary Diseases

May 22, 2024 — Voiant (USA) and Thirona (The Netherlands) announced they have entered a global commercial partnership ...

May 22, 2024

Cardiologist Brendan Carry, MD, and a team of Geisinger Medical Center physicians have enrolled the first patient in the U.S. into a cardiac amyloidosis trial. Image courtesy: Geisinger Medical Center/Mark Dastrup

News | Cardiovascular Clinical Studies

Geisinger Enrolls First Patient in Amyloid Cardiomyopathy Trial

May 20, 2024 — Cardiologist Brendan Carry, MD, and a team of Danville, PA-based Geisinger Medical Center physicians have ...

May 20, 2024

Baseline characteristics from FINE-HEART analysis highlight complex interplay between cardiovascular, kidney, and metabolic health, with over 92% of patients presenting two or more conditions

News | Cardiovascular Clinical Studies

Study Design and Baseline Characteristics of Prespecified, Exploratory Pooled Analysis to Investigate Effect of Finerenone on Cardio-Kidney Outcomes in Patients with CKD and Type 2 Diabetes/Heart Failure

May 17, 2024 — The study design and baseline characteristics of FINE-HEART, a new prespecified, exploratory pooled ...

May 17, 2024

Lahey Health Medical Center Investigator Leads Phase 3 trial demonstrating novel therapy enhances exercise capacity, improves symptoms in patients obstructive HCM

News | Cardiovascular Clinical Studies

New Treatment in Pipeline for Patients with Hypertrophic Cardiomyopathy

May 14, 2024 — One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the ...

May 14, 2024

News | Cardiovascular Clinical Studies

SHINE Trial Sheds Light on Deadly Stroke Complication

May 14, 2024 — An ambitious, nationwide clinical trial led by UVA Health’s Karen Johnston, MD, has provided doctors with ...

May 14, 2024

Represents the third patent granted to Tenax since March of 2023 protecting the use of levosimendan in the treatment of PH-HFpEF

News | Pharmaceuticals

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

May 6, 2024 — Tenax Therapeutics, Inc., a Phase 3, development-stage pharmaceutical company focused on identifying ...

May 06, 2024

A multicenter study led by Vanderbilt University Medical Center (VUMC) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure, a leading cause of hospitalization and death

News | Heart Failure

Advance in the Treatment of Acute Heart Failure Identified

April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center (VUMC) and Lipscomb University College ...

April 30, 2024

Phase 2 trial shows early signs that the investigational drug could relieve symptoms and improve exercise capacity in HCM patients with no other evidence-based treatment options available

News | Cardiovascular Clinical Studies

Ninerafaxstat Well-Tolerated and Safe for Nonobstructive Hypertrophic Cardiomyopathy

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

April 09, 2024

Participants saw 35% reduction in LDL cholesterol, signaling the process could offer safe, effective non-prescription use of life-saving drug

News | Cardiovascular Clinical Studies

Study Shows Web App Effective in Determining Access to Statins Without a Prescription

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

April 09, 2024

Novel drug shows promise for treating severe hypertriglyceridemia in patients at high risk for pancreatitis

News | Cardiovascular Clinical Studies

Plozasiran Reduces Triglyceride Levels by 74% at 24 Weeks

April 7, 2024 — In patients with severely elevated triglyceride levels at risk for developing acute pancreatitis, the ...

April 07, 2024